Sermorelin vs CJC-1295 research in Canada compares these two GHRH receptor agonists for their differential pharmacological profiles, half-lives, and GH axis stimulation characteristics. Sermorelin (GHRH 1-29 NH2) is a truncated, bioactive fragment of endogenous GHRH that produces short-duration, physiologically pulsatile GHRH receptor activation. CJC-1295 (with or without DAC) is a modified GHRH analogue with significantly extended half-life through either albumin-binding conjugation (DAC) or substitution of protease-sensitive residues (No DAC). Canadian neuroendocrinology researchers use both peptides to study GHRH receptor pharmacology and GH axis biology.
Half-Life and GH Pulse Duration Research
Sermorelin has a plasma half-life of approximately 10-20 minutes, closely mimicking endogenous GHRH and producing short GH pulses compatible with natural somatotroph cycling. CJC-1295 No DAC extends half-life to 30 minutes, while CJC-1295 DAC extends to 6-8 days through albumin binding. Canadian researchers study how these dramatically different pharmacokinetic profiles translate to different GH secretion patterns — pulsatile vs sustained baseline elevation — and their downstream effects on IGF-1 axis biology.
Receptor Pharmacology Research
CJC-1295 contains amino acid substitutions (Ala2→Aib, Arg11→Lys11, Leu27→Nle27) that protect against DPP-4 and endopeptidase cleavage, explaining its extended bioactivity. Canadian peptide chemistry researchers study how these substitutions affect GHRH receptor binding affinity, receptor internalization kinetics, and GHS-R1a signal transduction efficiency relative to native GHRH and sermorelin.
Sourcing GHRH Analogues in Canada
Research-grade Sermorelin and CJC-1295 are available from EhBuddy Peptides in Canada. For laboratory research use only.
